NextCure, Inc. filed a Form 8-K on November 20, 2026, disclosing that its board of directors set December 8, 2026 as the record date for the Pre-Closing Distribution of contingent value rights to stockholders, in connection with the company's pending merger with Avere Therapeutics, Inc.

Key Highlights

  • Record date set: The board determined December 8, 2026 as the record date, described in the filing as "the third business day prior to the anticipated First Effective Time."
  • Distribution date expected: The Pre-Closing Distribution is expected to occur on December 14, 2026, one business day after the First Effective Time.
  • One CVR per share: Each holder of record of Common Stock or Preferred Stock will receive one contingent value right for each share held as of the record date.
  • CVR economic terms: Each CVR represents the right to receive 90% of gross proceeds, if any, from any sale, transfer, license, or other disposition of the company's pre-merger legacy assets during the CVR Term, less permitted deductions.
  • Condition on payment: Payment of the Pre-Closing Distribution is conditioned on the occurrence of the First Effective Time.
  • Merger agreement origin: The underlying Merger Agreement was entered into on July 14, 2026, among NextCure, Avere Therapeutics, Neptune Merger Sub Corp., and Neptune Second Merger Sub, LLC.

NextCure Board Sets CVR Distribution Timeline Ahead of Avere Merger Close

According to the filing, NextCure, Inc. (NASDAQ:NXTC), a Delaware corporation headquartered at 2850 Quarry Lake Drive, Suite 280, Baltimore, Maryland, disclosed on November 20, 2026 that its board of directors had determined the specific dates governing the Pre-Closing Distribution of contingent value rights. The company entered the Merger Agreement with Avere Therapeutics on July 14, 2026, and the CVR mechanism was established as part of that transaction structure to provide stockholders with a potential future economic interest tied to NextCure's legacy pipeline assets.

The filing states that each CVR will represent a contractual right, governed by the CVR Agreement attached as Exhibit E to the Merger Agreement, to receive 90% of gross proceeds derived from any consideration paid to the company during the CVR Term as a result of "the sale, transfer, license or other disposition of rights to develop and commercialize the Company's pre-merger legacy assets during the CVR Term, less permitted deductions set forth in the CVR Agreement." The filing specifies that CVR holders will receive such proceeds, if any, only upon the occurrence of certain events set forth in, and subject to, the CVR Agreement. No assurance of any proceeds is stated in the filing.

The 8-K was filed under Item 7.01 Regulation FD Disclosure and was also checked as a written communication pursuant to Rule 425 under the Securities Act. The filing notes that the company filed a Form S-4 containing a proxy statement/prospectus with the SEC in connection with the proposed transaction, and directs investors to review those documents. The report was signed by Steven P. Cobourn, Chief Financial Officer of NextCure, Inc.

What Was Disclosed

NextCure's board set December 8, 2026 as the record date and December 14, 2026 as the expected distribution date for a Pre-Closing Distribution of contingent value rights to holders of its Common Stock and Preferred Stock, in connection with the pending merger with Avere Therapeutics. Payment is conditioned on the First Effective Time occurring.